Study of Kidney Circulating Cell-free DNA in Patients With Acute Kidney Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-10

Study Completion Date

2023-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The amount of total circulating DNA has been shown to increase in patients with acute renal failure. Nevertheless, it is currently not currently possible to prove the renal origin of this circulating DNA. Recently, in healthy subjects, teams have shown that it is possible to identify its tissue origin of circulating DNA. CGenetix is a MedTech company which develops on an identical principle an in vitro diagnostic test capable of identifying and quantifying renal degradation during an acute trauma. The objective of this study is to evaluate the sensitivity of the proposed technology to detect circulating DNA of renal origin released into the general circulation in patients with acute organic and functional renal failure. Patients with functional or organic kidney deficiency will be included and the kidney biomarkers develop by CGenetix will be compared between these 2 groups of patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.

NCT06646328

Acute Kidney Injury

TERMINATED PHASE4

Kidney Disease Biomarkers

NCT00255398

Kidney Disease Glomerular Disease Idiopathic Nephrotic Syndrome +2 more

COMPLETED

Variability in Micro-CT Imaging Results to Quantify Dialyzer Clotting

NCT06140563

Hemodialysis Complication Anticoagulants

COMPLETED NA

GENomic Predictors in A Multi-Ethnic Population With Kidney Disease Study

NCT06828562

Kidney Disease

ENROLLING_BY_INVITATION

A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients

NCT01236820

Cardiovascular Disease Chronic Kidney Disease Patients Hemodialytic Patients +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

When the patient arrives, a first stage of checking the inclusion/non-inclusion criteria will be respected. Patients who do not meet the eligibility criteria will not be sampled (pre-screening stage).

Patients meeting the eligibility criteria will be informed of the study by the investigator and a written information note will be given to them. If they do not object to their participation, an additional tube of blood for research purposes will be taken during a blood sample taken as soon as they are admitted as part of their usual treatment. They will also follow the standard care protocol according to the clinical recommendations of their attending physician. The objective of early sampling is to sensitize the test by assaying the marker as soon as possible after renal injury. In the event of a posteriori differential diagnosis (obstructive ARF or IRC), the patient will be excluded from the final analysis.

Patients passing the pre-screening and screening stages positively will be included in the final analysis.

90 patients should be included and divided into 2 groups:

* 65 patients with non-biopsied organic acute kidney injury of which 20 patients with biopsied organic acute kidney injury (test group)
* 25 patients with functional acute kidney failure (control group).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

functional kidney failure patients

Patients admitted to the nephrology department with suspicion of functional acute renal failures

Blood sampling

Intervention Type DIAGNOSTIC_TEST

One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes

Organic kidney injury patients

Patients admitted to the nephrology department with suspicion of organic acute renal failure (kidney injury)

Blood sampling

Intervention Type DIAGNOSTIC_TEST

One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling

One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years old
* Admitted for suspicion of acute renal injury (organic) and/or with an indication for renal biopsy (PBR)
* Patients hospitalized with functional acute renal failure (negative control and inclusion limited to n = 30 maximum)

Exclusion Criteria

* Patients \< 18 years old
* Patients with cognitive and mental disorders making them unable to express their non-objection to participation in the study
* Patients with obstructive renal failure
* Patients with chronic renal failure
* Patients who expressed their refusal to participate in the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No